KAILERA THERAPEUTICS, INC. COMMON STOCK
NASDAQ: KLRA (Kailera Therapeutics, Inc.)
Last update: 2 hours ago11.99
-0.84 (-6.55%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Kailera Therapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bain Capital Investors Llc | 30 Jun 2026 | 26,255,581 |
| Bain Capital Life Sciences Investors, Llc | 30 Jun 2026 | 22,583,268 |
| Canada Pension Plan Investment Board | 30 Jun 2026 | 7,304,688 |
| Atlas Venture Life Science Advisors, Llc | 30 Jun 2026 | 5,171,282 |
| Price T Rowe Associates Inc /Md/ | 30 Jun 2026 | 3,534,410 |
| Adage Capital Partners Gp, L.L.C. | 30 Jun 2026 | 3,208,286 |
| Siren, L.L.C. | 30 Jun 2026 | 2,214,286 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |